Kidney Disease Clinical Trials

Showing 1121-1140 of 3,346 trials

Clinical Outcomes and Costs of 4-Week Versus 6-Week Bloodwork for Patients on Hemodialysis

NCT03659500

The objective of this quality improvement study was to determine the effect of an institution-wide switch of routine bloodwork from four-week intervals to six-week intervals on the achievement of anemia and chronic kidney disease-mineral and bone disorder (CKD-MBD) targets for patients on chronic hemodialysis.

End Stage Renal Disease

Samuel Silver400 participantsStarted Jun 2012

UNKNOWNNA

Comparison of the Efficacy and Safety of SGLT2i and GLP-1 Receptor Agonists in Obese Patients With Kidney Disease

NCT06344247

The goal of this clinical trial is to exploring the changes in 24-hour urinary protein and renal function in obese patients with kidney disease after the application of sodium glucose cotransporter 2 inhibitors (SGLT2i) and glucagon like peptide-1 receptor agonists (GLP-1RA). Eligible patients were randomly and non-blindly allocated to four groups in a 1:1:1:1 ratio.The first group is the optimized treatment group, and patients in this group maintain the maximum dose/maximum tolerated dose of RAS blocker therapy. The second group is the optimized treatment + SGLT2i group. Participants in this group are titrated to the target dose (10 mg qd) in combination with dapagliflozin on the basis of optimized treatment. The third group is the optimized treatment + GLP-1RA group. Participants in this group will be titrated to the target dose (1mg qw) in combination with semaglutide on the basis of optimized treatment. The last group is the optimized treatment + SGLT2i + GLP-1RA treatment group, that is, based on the optimized treatment, combined with dapagliflozin titrated to the target dose (10 mg qd) and semaglutide titrated to the target dose (1 mg qw).

ObesityChronic Kidney Diseases

RenJi Hospital48 participantsStarted Sep 2023

Shanghai, Shanghai Municipality, China

Clinical Outcomes and Costs of 4-Week Versus 6-Week Bloodwork for Patients on Hemodialysis

Comparison of the Efficacy and Safety of SGLT2i and GLP-1 Receptor Agonists in Obese Patients With Kidney Disease

Related Searches

Therapeutic Drug Use for CKD Patients

Drug-drug Interaction Study of HRS-1780 Tablets in Healthy Subjects

Activity Trackers for Improving BP

Impact of the Composition of Packed Red Blood Cell Supernatant on Renal Dysfunction and Posttransfusion Immunomodulation

Neohepatic Albumin-Bilirubin Scores on Renal Outcomes in Living-donor Liver Transplantation Recipients

Side-specific Factors for Conversion in Adrenalectomy for Pheochromocytoma.

Interest of the SPECT-CT Scan SUVspect in the New Generation of Gamma-cameras With Semiconductor

Putting Patients at the Center of Kidney Care Transitions (PREPARE NOW)

The Microcirculation, Dialysis Modality and Sequestered Salt

Set-up of a Platform for Personalized Diagnosis of Rare Kidney Diseases (NIKE)

Clinical Trial to Evaluate Safety of Allogeneic Bone Marrow Derived Mesenchymal Stem Cell in Chronic Kidney Disease

Flexible Ureteroscopy With and Without Ureteral Access Sheath in Treatment of Large Renal Stones

Validation, Implementation, and Cost-analysis of a Strategy for Personalized Diagnosis of Rare Kidney Diseases

Thulium Beam Coagulation Versus Suture Renorrhaphy for Hemostasis of Tumor Bed in Laparoscopic Partial Nephrectomy

Cardiometabolic Devices Accuracy Study

Microwave Ablation With MRI-Guided SBRT Boost in Renal Cell Carcinoma

SELF-BREATHE RCT for Chronic Breathlessness

Fruquintinib Plus Everolimus as 2nd Line Therapy of ccRCC Patients Progressed Post IO and TKI Therapy